Preparing the Way: Exploiting Genomic Medicine to Stop Smoking

Laura J. Bierut, Rachel F. Tyndale

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Clinical medicine of the future is poised to use an individual's genomic data to predict disease risk and guide clinical care. The treatment of cigarette smoking and tobacco use disorder represents a prime area for genomics implementation. The genes CHRNA5 and CYP2A6 are strong genomic contributors that alter the risk of heaviness of smoking, tobacco use disorder, and smoking-related diseases in humans. These biomarkers have proven analytical and clinical validity, and evidence for their clinical utility continues to grow. We propose that these biomarkers harbor the potential of enabling the identification of elevated disease risk in smokers, personalizing smoking cessation treatments, and motivating behavioral changes. We must prepare for the integration of genomic applications into clinical care of patients who smoke.

Original languageEnglish
Pages (from-to)187-196
Number of pages10
JournalTrends in Molecular Medicine
Issue number2
StatePublished - Feb 2018


  • addiction
  • genetics
  • genomic medicine
  • smoking
  • smoking cessation


Dive into the research topics of 'Preparing the Way: Exploiting Genomic Medicine to Stop Smoking'. Together they form a unique fingerprint.

Cite this